PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: The Scott Partnership

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Novozymes Biopharma Invests in New cGMP Facility for Production of Bacillus-based Hyaluronic Acid - Novozymes Biopharma, part of Novozymes, world leader in bio-innovation, today announced the construction of a new cGMP facility at the company's existing site in Tianjin, China that will enable its novel form of Bacillus-based Hyaluronic Acid (bHA)
Novozymes Biopharma Invests in New cGMP Facility for Production of Bacillus-based Hyaluronic Acid

 

NewswireToday - /newswire/ - Nottingham, United Kingdom, 2009/04/27 - Novozymes Biopharma, part of Novozymes, world leader in bio-innovation, today announced the construction of a new cGMP facility at the company's existing site in Tianjin, China that will enable its novel form of Bacillus-based Hyaluronic Acid (bHA).

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Medical Services/Equipment Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

HyaCare, to be used within the bio-medical and pharmaceutical industries.

With a significant investment of over DKK 300 million, this new facility will produce bHA products to pharmaceutical grade Q7, paving the way for use in medical devices and pharmaceutical applications. Novozymes Biopharma are setting a new benchmark for the production of HA for applications from ophthalmic surgery to drug delivery, with the launch of large-scale GMP Q7 production planned for Q1, 2011.

HyaCare is the world's first and only recombinant source of HA. HyaCare is produced using Novozymes Biopharma's patented, safe fermentation and purification technology which results in a highly consistent and pure product. The HyaCare process is completely free of animal derived components and produced without the use of organic solvents.

HA is traditionally derived from rooster combs or from strains of streptococcal bacteria, which may potentially result in safety risks from animal proteins, viruses or endotoxins. Novozymes Biopharma developed this animal-free HA using a unique non-pathogenic method by fermentation of a well documented production strain, Bacillus subtilis. The Bacillus strain is a well-characterised, endotoxin free organism that is generally regarded as safe by the US Food and Drug Administration (FDA). Bacillus HA is identical to natural HA and will be backed by a safety package to support API applications.

"The strategic decision to build this new facility was based on a thorough market review and the increasing demand for bHA. Regulators are ever more cautious with regards to the safety of products and so a cGMP compliant facility is an essential part of our strategy in bringing bHA forward for use in medical device and pharmaceutical applications," comments Hans Ole Klingenberg, Director, Novozymes Biopharma. "China was an obvious choice as we already have a world-class manufacturing operation there with more than 20 years experience. This site will also facilitate expansion as business opportunities develop."

About Novozymes
Novozymes (novozymes.com) is the world leader in bioinnovation. Together with customers across a broad array of industries we create tomorrow's industrial biosolutions, improving our customers' business and the use of our planet's resources.

With over 700 products used in 130 countries, Novozymes' bioinnovations improve industrial performance and safeguard the world's resources by offering superior and sustainable solutions for tomorrow's ever-changing marketplace.

Novozymes' natural solutions enhance and promote everything from removing trans fats in cooking, to advancing biofuels to power the world tomorrow.
Our never-ending exploration of nature's potential is evidenced by over 6,000 patents, showing what is possible when nature and technology join forces.

Our 5,000+ employees working in research, production and sales around the world are committed to shaping business today and our world tomorrow.

Contacts:
Novozymes Biopharma
Sally Vernon, Marketing Communications Manager

Corporate Contacts:
Press and media:

Johan Melchior
T: +45 4446 0690
M: +45 3077 0690
René Tronborg
T: +45 4446 2274
M: +45 3077 2274
Paige Donnelly (USA)
T: +1 919 494 3209
M: +1 919 218 4501

Investor relations:
Camilla Kinch Jensen
T: +45 4446 0852
M: +45 3077 0852
Tobias Bjørklund (USA)
T: +1 919 494 3483
M: +1 919 649 2565

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Medical Services/Equipment Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: The Scott Partnership

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 
 
  Your Banner Ad showing on ALL
Medical Services/Equipment articles,
CATCH Visitors via Your Competitors Announcements!


Novozymes Biopharma Invests in New cGMP Facility for Production of Bacillus-based Hyaluronic Acid

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Fiona Robisnon 
+44 1477 539539 SYKE[.]novozymes.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any The Scott Partnership securities in any jurisdiction including any other companies listed or named in this release.

Medical Services/Equipment via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From The Scott Partnership / Company Profile


Read Medical Services/Equipment Most Recent Related Newswires:

Frost & Sullivan Recognizes Ventec Life Systems for New Product Innovation - Game-changing, Modular Respiratory System, VOCSN
BD Expands Genomics Portfolio with New Single Cell Platform for RNA Expression Analysis
GE Healthcare Advances the Delivery of Cell Therapies with New Thawing Technology
Ansell Limited Announces the Closing of the Sale of its Sexual Wellness Business
PQ Bypass Earns Frost & Sullivan’s European Technology Innovation Award for its Proprietary DETOUR System for Percutaneous Bypass
Curaçao EMS Uses ZOLL Autopulse to Save Tourist in Sudden Cardiac Arrest
ZOLL to Showcase Expanded Portfolio of AEDs at Caravan Salon 2017
MDxHealth Announces Service Agreement with Kaiser Southern California Permanente Medical Group
Frost & Sullivan Lauds CytoSorbents for Leading the Critical Care Immunotherapy Segment with its Novel Blood Purification Solution, CytoSorb®
MVZ Dr. Stein & Kollegen First German Medical Laboratory to Offer the SelectMDx for Prostate Cancer Test
Datalogic Announces New Healthcare Memor X3 HC Mobile Computer
Neuronix Ltd Announces the First Group of Mild to Moderate Alzheimer Patients to be Successfully Treated by The NeuroAD™ Therapy System
SelectMDx to be Distributed Across Middle East by IPS Genomix
GE Healthcare Partners with Oritain to Introduce Independent Test to Confirm Country of Origin of Fetal Bovine Serum
Saebo, Inc. Awarded Patent for Low-Profile Stroke Recovery Glove

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  JobsWare.com

Visit  RightITnow Ltd





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)